Navigation Links
Helix BioMedix to Discuss Potential of Its Proprietary Peptides at,the BIO International Convention

BOTHELL, Wash., April 18, 2007 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc. today announced that Timothy Falla, Ph.D, Chief Scientific Officer, will present an update on the company's new generation of small molecule peptide (lipohexapeptide) technology at the BIO International Convention. The convention will take place at the Boston Convention & Exhibition Center in Boston, MA from May 6th through 9th. Dr. Falla's presentation is scheduled for Wednesday, May 9th, Room D at 10:00 am.

Dr. Falla's presentation will discuss the company's research on the potential of lipohexapeptides as broad spectrum anti-infectives in the prevention of wound infections caused by multiple-resistant hard to treat pathogens such as Pseudomonas aeruginosa in burns, Staphylococcus aureus in surgical wounds and Acinetobacter baumannii in trauma wounds. The company's lipohexapeptides are designed specifically to overcome the disadvantages that have hampered the industry's previous attempts to develop therapeutic antimicrobial peptides. These 'new generation' peptides are excellent drug candidates due to their low toxicity, attractive cost of goods profile, and evidence of efficacy in both bacterial and fungal infection models.

Helix BioMedix's peptides are also currently bringing value-added performance benefits to the cosmeceutical and personal care markets in the areas of anti-acne and anti-aging skin care. The company believes that an increasing number of industry leaders and skin care clinicians are identifying peptides as the next generation of cosmetic skin care technology and the company's proprietary peptides are being incorporated into a growing number of products through various licensing agreements.

Helix BioMedix will be participating in the BIO Business Forum Partnering Program. In 2007, Helix BioMedix has plans to accelerate its entry into the arena of pharmaceutical topical anti-infectives with a focus on the large anti-infective dermatology market, including indications such as acne and dermatitis. The company also hopes to increase the number of peptide-enhanced personal care products that contain Helix BioMedix peptides in the next several years.

The Biotechnology Industry Organization (BIO), founded in 1993, is a nonprofit association that represents more than 1,100 biotechnology companies, state and international affiliates, and related organizations. BIO is widely known for the BIO International Convention, a four-day annual biotechnology showcase that draws about 20,000 attendees. The convention serves to educate the public and policymakers about biotechnology, while fostering partnering meetings and other business development activities that keep the industry growing.

About Helix BioMedix

Helix BioMedix, Inc. is a biopharmaceutical company with a vast library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. The company's mission is to enrich clinical practice and the patient and consumer experience by expanding opportunities to tap the health, beauty and safety benefits of advanced bioactive small molecule technology. Its vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptide technology.

The company's core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology. These areas of expertise are leveraged through relationships with contract research organizations and peptide manufacturers for the capability to take a program from theoretical concept to a validated and qualified skin care active with respect to both efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care, acne treatment and other topical anti-infective pharmaceuticals and w ound healing. In addition to our primary focus on peptides for dermatological applications, the company's peptide library also holds promise for advancements in other therapeutic and industrial areas such as oral care, biocides and animal health.

More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com .

Important Notice

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to our potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in our reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

    Contact:

    Investor Relations:

    Cameron Associates

    Alison Zieg
ler, 212-554-5469

    

alison@cameronassoc.com

CONTACT: investors, Alison Ziegler of Cameron Associates, +1-212-554-5469,, for Helix BioMedix, Inc. alison@cameronassoc.com

Web site: http://www.helixbiomedix.com/

Ticker Symbol: (NASDAQ-OTCBB:HXBM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
2. Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
6. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
7. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. New Information on the Potential of Plasmin Shared at ISTH Congress
10. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... its digital health technology platform, which specializes in ... programs into scalable digital products, Zillion enables companies ... and empower consumers to take control of their ... live video conferencing – including one-to-one, group and ...
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by ... and deal with these stressors is to adopt a more healthful diet, but too ... Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
Breaking Medicine News(10 mins):